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In the last years much attention has focused on the Th17 and Th1 phenotypes and
on their pathogenic role in juvenile idiopathic arthritis, investigating how the cytokines
produced by T helper cells act on resident cells on the synovia and which signal
transduction pathways regulate Th17 cells proliferation and plasticity. In this context,
an important milestone was represented by the identification of the non-classic Th1
phenotype, developed from the shift of Th17 cells. The cytokine TNF-α, beyond its
well-known proinflammatory activity is involved in this process and this is one of the
reasons why the TNF-α inhibitors are widely used in the treatment of juvenile idiopathic
arthritis patients.
Keywords: Th17, Th1, CD161+ T cells, TNF-α, synoviocytes
INTRODUCTION
Juvenile idiopathic arthritis (JIA) is one of the most common chronic conditions of childhood,
comprising several forms of arthritis characterized by persistent joint inflammation for at least 6
weeks, with an onset before the age of 16 years and with unknown cause (1, 2). The term JIA
covers seven pathologic conditions that differ for clinical presentation, disease course and treatment
response; in particular it includes systemic arthritis (sJIA), oligoarthritis, polyarthritis (both
rheumatoid factor positive or negative), psoriatic arthritis (JPsA), enthesitis-related arthritis (ERA),
and undifferentiated arthritis (1, 2). Although the cause of disease is unknown, immune cells,
including T and B lymphocytes, infiltrate the synovial membrane of inflamed joints, suggesting
that the adaptive immune system is involved in the pathogenesis of JIA (3). Human effector
CD4+ T lymphocytes can be classified in three main subsets based mainly on their immunological
functions, their cytokines production profile and their typical transcription factor expression (4).
Th1 lymphocytes express the transcription factor T-bet, produce interferon (IFN)-γ, and defend
the body from intracellular infections. Th2 cells express the transcription factor GATA-3, produce
type 2 cytokines (interleukin (IL)-4, IL-5, IL-9, and IL-13) and are important to protect against
helminths (5, 6). Finally, the Th17 subset produce IL-17A, IL-17F and IL-22 (7–10), express the
transcription factor ROR-γT (11–13) and the lectin receptor CD161 (14), as typical surface marker.
Beyond their protective role against extracellular bacterial and fungal infections, Th17 cells have
been demonstrated to be important in the pathogenesis of several autoimmune and inflammatory
diseases, including multiple sclerosis, inflammatory bowel disease (IBD), psoriasis, rheumatoid
arthritis (RA), and JIA (15, 16). In humans, Th17 lymphocytes are included within the CD161+
cell fraction of circulating and tissue-infiltrating CD4+ T cells, and they develop from a CD161+
T cell precursor found in umbilical cord blood and neonatal thymus (14, 17, 18).
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Since JIA can be considered as an immune-mediated
disorder, the pharmacologic therapy is essentially based on
immunosuppressive drugs, at least when the usage of non-
steroidal anti-inflammatory drugs (NSAIDs) does not control
symptoms. Among these disease-modifying antirheumatic drugs
(DMARDs) methotrexate (MTX), is considered the first line
treatment, since its positive clinical effects are associated with low
toxic effects (19). For those patients with a suboptimal response
to non-biologic DMARDs, in particular those with polyarthritis,
the usage of biologic drugs such as tumor necrosis factor-α
(TNF-α) inhibitors (etanercept, infliximab and adalimumab),
IL-1 inhibitors (anakinra, canakinumab, and rilonacept), IL-6
inhibitor (tocilizumab), CD20/B-cell targeted (rituximab) and T-
cell co-stimulatory signal blocker (abatacept), has been proven to
be effective (19–22).
T HELPER EFFECTOR CELLS IN
OLIGOARTICULAR JIA
The synovial membrane of JIA inflamed joints shows high
degree of infiltrating mononuclear cells, including T and B
lymphocytes, dendritic cells and macrophages (3, 18, 23). Among
T cells, Th1 are the most represented since these cells can
migrate in the synovia in response to the chemokine CXCL10
(24). For this reason, these cells were thought to play a key
role in the pathogenesis of oligoarticular JIA (25, 26), at least
until 10 years ago. More recently, after the identification of the
Th17 subset, many experimental data suggested their potential
pathogenic role both in adult and childhood arthritis as well as in
other inflammatory and autoimmune diseases (27, 28). Indeed,
increased levels of IL-17A and of the transcription factor ROR-
γT, as well as of Th17 cells were reported in the synovial fluid
(SF) of oligoarticular JIA patients (26, 28–31).
Moreover, Th17 cells have been demonstrated to
be pathogenic in several murine models of chronic
inflammatory disorders (16), such as experimental autoimmune
encephalomyelitis (7), collagen-induced arthritis (32), and
IBD (10–12).
However, despite their supposed pathogenicity, Th17 are very
rare at inflammatory sites if compared to Th1 cells (28, 33). A
first explanation for this rarity is a self-regulatory mechanism
that controls Th17 cells clonal expansion. In particular, ROR-γT
favors the up-regulation of the interleukin (IL)-4 induced gene
1 (IL4I1), which encodes an l-phenylalanine oxidase that down-
regulates CD3ε expression on T cells via the production of H2O2
(28, 34). By this way, Th17 cells display an impaired signaling
pathway downstream of the T-cell receptor (TCR), leading to
inappropriate proliferation and reduced IL-2 production upon
TCR triggering (28, 34). In addition, high IL4I1 expression
in Th17 cells induces up-regulation of Tob1, a member of
the Tob/BTG anti-proliferative protein family, involved in the
negative control of the cell cycle (35).
It has also been recently described that Th17 cells show
reduced IL-2 responsiveness since they express Musculin
(MSC), a member of the basic helix-loop-helix transcription
factors, dependent by ROR-γT, which negatively regulates the
phosphorylation level of STAT5B upon IL-2 signaling (36). In
agreement with these findings, both IL4I1 and MSC were found
to be selectively expressed by CD161+ T cells obtained from SF
of oligoarticular JIA inflamed joints (34, 36).
It has also been demonstrated that the development of JIA
and of other autoimmune diseases depends not only on the
amount and the phenotype of Th effector cells, but also on their
balance with Treg cells (37). Indeed, several papers demonstrated
an accumulation of Th17 and Treg cells in SF and PB of JIA
patients (31, 38, 39), in particular in active versus inactive JIA
(31), hypothesizing that the joint inflammatory status persists
despite the high frequency of Treg cells because Th17 cells show
a reduced susceptibility to their regulatory function. This could
be also related to the low proliferation rate of Th17 cells (33–36).
ROLE OF Th17 PLASTICITY IN THE
PATHOGENESIS OF OLIGOARTICULAR JIA
A second explanation for human Th17 cells rarity at inflamed
tissues is their phenotype plasticity (28). Indeed, in presence of
local inflammatory cytokines such as IL-12 and TNF-α, Th17
cells acquire the ability to produce IFN-γ. At a first stage, cells
display an intermediate phenotype known as Th17/Th1 and
produce both IFN-γ and IL-17, but they can also rapidly loose
IL-17 secretion and become IFN-γ single producers (12, 18, 40).
These Th17-derived Th1 cells are defined as non-classic Th1
cells because, differently from classic Th1 cells, they maintain the
expression of ROR-γT, CD161, and CCR6 (17, 18, 28, 40), typical
molecules of the Th17 subset (Figure 1).
Th17/Th1 and non-classic Th1 cells were found to be enriched
in the SF of oligoarticular JIA children compared to their
peripheral blood (18, 40). Moreover, a positive correlation
between the frequencies of CD4+CD161+ Th17/Th1 cells in
the SF of inflamed joints and disease activity parameters was
described (18, 28). The shift of Th17 cells toward the non-
classic Th1 phenotype is driven by IL-12, that has been found
to be elevated in the SF of oligoarticular JIA patients (18, 40).
Moreover, the finding that SF-derived Th17 clones share similar
TCR Vβ spectra with Th1 CD161+ clones but not with Th1
CD161- ones (18, 40), strongly supported the data of the shift
of Th17 toward non-classic Th1 cells. These findings are in
agreement with several studies describing an accumulation of
Th1 cells in the SF of JIA patients (25, 26), characterized as Th
cells producing IFN-γ but without any distinction between the
classic and non-classic phenotypes Additional data at epigenetic
level confirm that non-classic Th1 cells originate from Th17
(41); indeed it was observed that non-classic Th1 cells exhibit
demethylation of RORC2 and IL17A genes, as reported for Th17
cells, whereas classic Th1 cells are completely methylated at these
loci (41).
Th17 plasticity consists not only in the acquisition of the
ability to produce IFN-γ, but also GM-CSF (42). In fact, it has
been described an enrichment of GM-CSF producing T cells
with a non-classic Th1 phenotype in the SF of oligoarticular
JIA patients (42) and induced in vitro by IL-12. This data
suggests a possible involvement not only of IFN-γ but also
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FIGURE 1 | Similar and distinct features of human Th1 and Th17 cells. Both classic and non-classic Th1 cells produce IFN-γ, express the transcription factor T-bet
and Eomes and the surface marker CXCR3. Differently from classic, non-classic Th1 cells maintain also the expression of ROR-γT, CD161, and CCR6 as typical
transcription factor and surface markers of the Th17 phenotype. In fact, non-classic Th1 cells originate from the shift of Th17 toward the Th17/Th1 phenotype when in
the presence of IL-12 and/or TNF-α.
of GM-CSF in JIA pathogenesis, and, accordingly, a positive
correlation between GM-CSF protein levels in the SF and the
serum parameters of disease activity was described (42).
Moreover it has been recently described that human non-
classic Th1 cells development is promoted by the transcription
factors Eomes (43), which induces and reinforces IFN-γ
production, maintains the Th1 phenotype stability by inhibiting
and preventing the re-expression of ROR-γT and IL-17A and
promotes GM-CSF secretion (43). Finally, it was shown that
Eomes induces, in vitro, the production of IFN-γ and GM-
CSF by human CD4+ T cells and that cells with this cytokines
profile were enriched in the SF of inflamed joints of children
with oligoarticular JIA (43). All these data further support the
pathogenic role of Th17-derived non-classic Th1 cells.
Additional evidence of the pathogenic features of
CD4+CD161+ T cells, including pure Th17 cells and their
derivative phenotypes Th17/Th1 and non-classic Th1, derived
from a recent paper (44), describing that all these subsets
express CHI3L1. This chitinase-like protein without enzymatic
activity is defined in the literature as a well-known marker of
disease activity and inflammation in several immune-mediated
disorders (44–47): its levels are elevated in SF of children affected
by oligoarticular JIA and positively correlated to inflammatory
parameters (44).
These data of Th17 plasticity, partially solve the literature
debate on the pathogenic or protective role of Th17 cells in
immunomediated disorders (48, 49), supporting the hypothesis
that, at least in JIA, the Th1 subset, both classic and non-classic,
is directly involved in the active phase of the disease when the
clinical manifestations are evident, and that the pure Th17 cells
acquire a pathogenic feature when they start to produce IFN-γ
shifting toward the Th17/Th1 and the non-classic Th1 phenotype
(18, 20, 40). Anyway, it cannot be excluded that even pure Th17
cells may play a key role in the pathogenesis of JIA during the
onset and/or the early-phase of the disease.
CROSS TALK BETWEEN T HELPER CELLS
AND RESIDENT SYNOVIAL CELLS
CD4+ T helper lymphocytes orchestrate both RA and JIA
chronic inflammation producing cytokines that initiate and
maintain the process of synovial proteolysis and proliferation
as well as the angiogenesis related to the inflammatory status
(50, 51). Synovial fibroblasts (SFbs) are the main tissue resident
cell population in the synovia and it has been demonstrated
that in adult RA SFbs produce cytokines and matrix-degrading
enzymes, crucial to promote cartilage destruction and to mediate
inflammation (28, 52). In particular, it has been reported
(51) that SFbs derived from SF of oligoarticular JIA patients
express high levels of CD106 (VCAM), a sialoglycoprotein
which mediates leukocyte-endothelial cell adhesion and signal
transduction (51), and whose upregulation is critical to favor
leukocytes retention in the inflamed synovia (51). SFbs also
showed a peculiar morphology consisting in polygonal cell body,
large, and oval-shaped nucleus, many slender protrusions and
branches extended out of the cell body (51, 53). This peculiar
phenotype of oligoarticular JIA-derived SFbs, was resembled in
vitro stimulating healthy-derived SFbs with culture supernatants
from activated classic and non-classic Th1, but not from Th17,
lymphocytes. Indeed, also in these experimental conditions SFbs
upregulated CD106 expression and underwent morphological
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FIGURE 2 | Role of different T helper cell subsets in the pathogenesis of oligoarticular juvenile idiopathic arthritis. IL-17A and TNF-α produced by Th17 and Th17/Th1
cells infiltrating the inflamed joints of oligoarticular juvenile idiopathic arthritis patients, promotes IL-6 and IL-8 release by endothelial cells and synoviocytes in the
synovial membrane. These cytokines, in turn, maintain joint inflammation and induce leukocytes recruitment. Inflamed joints are also characterized by high IL-12 and
TNF-α levels, which promote Th17 cells phenotypic shift toward Th17/Th1 and non-classic Th1 cells. Non-classic Th1 cells proliferate at higher rate than Th17, and
together with classic Th1 cells secrete IFN-γ and TNF-α, favoring the expression of the adhesion molecule CD106 by synoviocytes. Anti-TNF-α treatment can reduce
inflammation via both impairing Th17 cell phenotypic shift and also inhibiting CD106 upregulation on the synovial membrane.
changes (50). It has been demonstrated that TNF-α is the main
cytokine involved in this process and that IFN-γ exerts a synergic
effect (51, 54). The concept that cytokines produced by T cells
play an important role on the activation of SFbs has been
confirmed also by the paper of Lavocat et al. (55). It demonstrates
with in vitro experiments that IL-17A and TNF-α alone are able
to induce the expression of IL-6 and IL-8 (55) by both endothelial
cells and synoviocytes (even if with different kinetics on each
cell type), and that a synergistic effect can be achieved from
the use of both cytokines (55). Similar results were obtained
also by stimulating endothelial cells and synoviocytes in the
presence of culture supernatants from activated T cell clones
or recombinant cytokines. Indeed, the main increase in IL-6
and IL-8 production was observed when cells were cultured
in presence of supernatants from Th17/Th1T cell clones that
contained both IL-17A and TNF-α (55). The early expression
of IL-8 in inflamed joints, directly produced also by Th17 cells
itself (9), might explain the massive neutrophil recruitment
in the acute phase (56). On the other hand, IL-6 production
might be important to sustain the pro-inflammatory process
since it is involved in the differentiation and expansion of Th17
cell (57), in VEGF production [thus mediating angiogenesis
(58)], as well as in antibody production (59) and in osteoclast
activation (55).
The IL-17 signature, which is typical of JIA, is important
also for bone and cartilage erosion. In fact, it has been
demonstrated that IL-17A acts on SFbs increasing the expression
of different types of matrix metalloproteinases, MMP-1, MMP-
3 (60). Finally, it is important to note that IL-17A production
is not strictly associated to Th17 cells, since it is produced
also by additional cells of the immune system enriched in SF
of JIA patients, such as CD3+CD8+ and CD3+CD4-CD8- T
cells (17, 61, 62) and innate lymphoid cells (62). Collectively,
these data suggest that mechanisms actively contributing to
joint inflammation in the synovia of JIA patients depend
on the final balance and cross-talk between tissue resident
cells and immune cells from both the adaptive and innate
immune systems.
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EFFECTS OF BIOLOGICAL DRUGS IN THE
TREATMENT OF JIA: EX-VIVO AND
IN-VITRO OBSERVATIONS
Cytokines produced by immune cells (in particular T cells
and monocytes) and by tissue resident cells in the synovia
contribute to the development of JIA and are responsible
for most of the clinical manifestations of the disease. In this
view, pro-inflammatory cytokines represent a key therapeutic
target for biological treatment. The drugs mainly used and
effective in JIA inhibit the activity of TNF-α, IL-1, or IL-
6. TNF-α has pleiotropic effects in the inflamed environment
of affected joints, acting on different cell populations (51):
TNF-α mediates monocyte, macrophage and SFb activation,
and it is also responsible for inflammation induction, cartilage
degradation, bone erosion and tissue damage (51). Moreover, as
previously stated, TNF-α acts on SFbs inducing the upregulation
of CD106, thus favoring leukocytes retention within the synovia
and increasing joint inflammatory status (51). TNF-α is also
involved in the neovascularization process, leading to synovial
membrane growth, and in the process of osteoclast-containing
’pannus’ formation (51). Additionally, TNF-α interferes with
T helper cells phenotype plasticity, mediating the shifting
of Th17 lymphocytes toward non-classic Th1 cells (20,
51). Nowadays, JIA patients are treated with non-steroidal
antiinflammatory drugs, corticosteroids, and disease modifying
antirheumatic drugs including TNF-α antagonists (28). Among
these antagonists etanercept is a soluble dimeric fusion protein
binding soluble TNF-α. Etanercept has been reported to induce
improvement of clinical symptoms (as measured by radiological
progression and laboratory parameters of disease activity) in
patients affected by immune-mediated arthritis, including RA,
JIA, and psoriatic arthritis (28, 63). Moreover, etanercept efficacy
in JIA treatment has been demonstrated in randomized clinical
trials, as well as in long-term observational registries (28, 64).
These clinical effects were sustained by its well-known anti-
inflammatory properties on the innate and adaptive immune
responses. Moreover, it has been reported a new mechanism of
action of etanercept, defining its inhibitory role in the plasticity
of Th17 cells toward the non-classic Th1 phenotype mediated by
TNF-α (18, 20, 28). In fact, etanercept reduces the proportion
of circulating non-classic Th1 cells (20), supposed to play a
key role in the pathogenesis of oligoarticular JIA and leads
to an increased frequency of Th17 cells (20). Similar evidence
was observed also during the treatment of RA patients with
adalimumab, a fully humanized monoclonal IgG1 antibody
against TNF-α (65), supporting again the important role of
this cytokine in the pathogenesis of such diseases. In fact,
after 12 weeks of treatment an increase was found in the
frequency of IL-17A producing cells that significantly correlated
with a reduction in joint inflammation (65, 66). These data
support again the important role of this cytokine in the
pathogenesis of such diseases. Moreover, it was demonstrated
that etanercept acts also on the regulation of CD106 expression
on SFbs, in fact in vitro administration of this drug negatively
interferes with the ability of both classic and non-classic
Th1cells supernatants to significantly induce CD106 expression
on SFbs (51). Taking into account the important role of CD106
expression on SFbs to mediate leukocytes adhesion, these recent
data define also the role of etanercept in interfering with the
adhesion of immune cells on SFbs. Even if these data were
obtained with in-vitro experimental models (51), they may
suggest that the reduction of inflammatory cells in the synovia,
occurring during etanercept treatment of oligoarticular JIA, may
be driven by the reduced retention of immune cells within
inflamed joints.
All these data define the immunomodulatory properties of
TNF-α inhibitors, especially of etanercept and adalimumab,
which could further explain its disease-modifying effect in JIA
(20, 51, 66). Regarding infliximab (a human–mouse chimeric
anti-TNF-α antibody) and golimumab (a fully humanized
monoclonal anti-TNF-α antibody), their use is related mainly
to polyarticular JIA and reported in case reports and open-label
trials (22).
Among additional drugs inhibiting inflammatory cytokines,
the IL-6 receptor antagonist (tocilizumab) and the IL-1
antagonists (anakinra, canakinumab and rilonacept), are
currently used in systemic JIA. Anyway these drugs were also
tested in clinical practice for oligoarticular or polyarticular JIA
(22, 67), and their efficacy may be due, at least in part, to the
interference with Th17 expansion and differentiation in the
synovia mediated by IL-1 and IL-6.
Moreover, the use of anti-IL-12/IL-23 p40 inhibitors could
improve the course of JIA, since both cytokines are involved
in Th1 and Th17 differentiation and are important regulators
of Th17 plasticity. Ustekinumab, the human monoclonal
antibody anti- p40 subunit, is often used in the treatment
of psoriatic arthritis and ankylosing spondylarthritis in adults
and children (68) and its use in oligoarticular JIA is poor.
These data suggest that although these cytokines contribute
to joint inflammation, they may not be the principal factors
responsible and it is likely that other key mediators are involved
(i.e., TNF-α).
Similarly, the use of anti-IL-17A in the treatment of JIA
has been explored. In fact data from clinical trials show that
secukinumab, the high-affinity fully humanmonoclonal antibody
neutralizing the activity of IL-17A, can be effective in the
treatment of JPsA and ERA, suggesting that IL-17 cytokine
and Th17 cells play a key role in the pathogenesis of these
subtypes of JIA and their role is instead marginal in oligoarticular
JIA (18, 20, 40). These data suggest that the use of the
appropriate treatment and its effectiveness are related to the
different biological conditions found in the different subtypes
of JIA (69).
Finally, since oligoarticular JIA is mainly considered to arise
due to a dysregulated adaptive immunity, involving Th1 and
Th17 effector cells and Treg cells, abatacept was used for
its treatment. Abatacept is a chimeric CTLA4 and IgG Fc
fusion protein, that, binding to CD80/86 molecules instead
of CD28, reduces T helper cells activation. In the treatment
of oligoarticolar JIA, it has been demonstrated that abatacept
reduced proliferation of CD4+ T cells and their cytokines
production (mainly IFN-γ and TNF-α) (21) and reduced the
induction of Ig production by B cells (70).
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CONCLUSION
In this review, we analyzed the role of different types of T
helper cell subsets in the pathogenesis of JIA with particular
attention to Th17 and Th1 phenotype (Figure 2). Both Th1
and Th17 cells are critical for the pathogenensis of the
disease: Th1 lymphocytes through the production of pro-
inflammatory cytokines IFN-γ and TNF-α; Th17 lymphocytes
thanks to the shift toward the non-classic Th1 phenotype.
Th1 cells subsets exert their function through inducing the
expression of CD106 on SFbs, which is crucial in mediating
immune cells retention in inflamed synovia. Intriguingly the
TNF-α inhibitors are the main biological drugs used in JIA
and interfere both with the shift of Th17 to Th1 cells
and the TNF-α mediated CD106 upregulation on SFbs. All
these data give an explanation at both cellular and molecular
level for the efficacy of etanercept treatment in JIA and
represent the beginning for further investigation with the aim
to identify more specific therapeutic targets. In this view,
it is important to underline that different subtypes of JIA
are characterized by different inflammatory conditions, whose
characterization is crucial for the choice of the efficacious
biological treatment.
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